ClinicalTrials.gg

Program

zilovertamab vedotin

Also written as “Zilovertamab vedotin” and “Zilovertamab Vedotin”.

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Carcinoma, Transitional Cell · Burkitt Lymphoma · Triple Negative Breast Neoplasms, led by Merck.

Furthest: phase 3, since Nov 11, 202110 company-led studies, 7 open or runningNext primary completion: Sep 24, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck107 open or runningphase 3since Nov 11, 2021Feb 4, 2019Sep 24, 2027phase 3 · NCT05139017
  • Named in Merck’s own pipeline as zilovertamab vedotin (MK-2140), phase 3, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 4, 2019First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT03833180 · 91 enrolled · United States
  2. Aug 4, 2020Phase 2 study in Triple Negative Breast NeoplasmsNCT04504916 · 102 enrolled · United States, Canada
  3. Nov 11, 2021Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT05139017 · 290 planned · United States, Argentina, Australia and more
  4. Nov 22, 2021Phase 2 study in RecurrenceNCT05144841 · 140 enrolled · United States, Canada, Chile and more
  5. Jun 1, 2022Phase 2 study in LymphomaNCT05406401 · 60 enrolled · Canada, Israel, Italy and more
  6. Jul 11, 2022Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05458297 · 189 enrolled · United States, Brazil, Canada and more
  7. Sep 28, 2022Phase 2 study in Carcinoma, Transitional CellNCT05562830 · 48 enrolled · United States, Australia, Canada and more
  8. Feb 1, 2024Phase 2 study in Burkitt LymphomaNCT06395103 · 90 planned · United States, Australia, Belgium and more
  9. Dec 2, 2024Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT06717347 · 1,046 planned · United States, Argentina, Australia and more
  10. Mar 20, 2025Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT06890884 · 594 planned · United States, Belgium, Germany and more

Ahead

  1. Sep 24, 2027Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT05139017
  2. Dec 13, 2027Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT06890884
  3. Feb 26, 2029Primary completion: phase 2 study in Carcinoma, Transitional CellNCT05562830
  4. Mar 31, 2029Primary completion: phase 2 study in Burkitt LymphomaNCT06395103

TargetBeta

“An antibody-drug conjugate (ADC) composed of zilovertamab, a humanized, immunoglobulin G (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) conjugated, via a proteolytically cleavable linker, to the auristatin derivative an…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of zilovertamab, a humanized, immunoglobulin G (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) ”NCIt, by rule

Other programs on ROR1

ProgramCompanyFurthest phaseStudies
Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07ruleshanghai-epimab-biotherapeutics-co-ltdphase 22
TQB2101Sino Biopharmaceuticalphase 12
Anti-ROR1 Antibody-drug Conjugate IM-1021ruleImmunomephase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06890884Lymphoma, Large B-Cell, Diffuse · United States, Belgium, Germany and more2RecruitingDec 13, 2027594
NCT06717347Lymphoma, Large B-Cell, Diffuse · United States, Argentina, Australia and more3RecruitingJul 2, 20291,046
NCT06395103Burkitt Lymphoma · United States, Australia, Belgium and more2RecruitingMar 31, 202990
NCT05562830Carcinoma, Transitional Cell · United States, Australia, Canada and more2Active, not recruitingFeb 26, 202948
NCT05458297Leukemia, Lymphocytic, Chronic, B-Cell · United States, Brazil, Canada and more2Active, not recruitingMay 17, 2029189
NCT05406401Lymphoma · Canada, Israel, Italy and more2Active, not recruitingApr 26, 202960
NCT05144841Recurrence · United States, Canada, Chile and more2CompletedApr 21, 2026140
NCT05139017Lymphoma, Large B-Cell, Diffuse · United States, Argentina, Australia and more3RecruitingSep 24, 2027290
NCT04504916Triple Negative Breast Neoplasms · United States, Canada2TerminatedJun 12, 2023102
NCT03833180Leukemia, Lymphocytic, Chronic, B-Cell · United States1CompletedDec 18, 202391

How it is read

Names in the registry

  • “Zilovertamab vedotin”, 9 entries
  • “Zilovertamab Vedotin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.